Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
Wada H, Isobe M, Kakimi K, Mizote Y, Eikawa S, Sato E, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Yamasaki M, Miyata H, Matsushita H, Udono H, Seto Y, Yamada K, Nishikawa H, Pan L, Venhaus R, Oka M, Doki Y, Nakayama E. Wada H, et al. Among authors: udono h. J Immunother. 2014 Feb-Mar;37(2):84-92. doi: 10.1097/CJI.0000000000000017. J Immunother. 2014. PMID: 24509171 Clinical Trial.
Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient.
Miyai M, Eikawa S, Hosoi A, Iino T, Matsushita H, Isobe M, Uenaka A, Udono H, Nakajima J, Nakayama E, Kakimi K. Miyai M, et al. Among authors: udono h. PLoS One. 2015 Aug 20;10(8):e0136086. doi: 10.1371/journal.pone.0136086. eCollection 2015. PLoS One. 2015. PMID: 26291626 Free PMC article.
Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide.
Eikawa S, Kakimi K, Isobe M, Kuzushima K, Luescher I, Ohue Y, Ikeuchi K, Uenaka A, Nishikawa H, Udono H, Oka M, Nakayama E. Eikawa S, et al. Among authors: udono h. Int J Cancer. 2013 Jan 15;132(2):345-54. doi: 10.1002/ijc.27682. Epub 2012 Jul 11. Int J Cancer. 2013. PMID: 22729530 Free article.
Immune-mediated antitumor effect by type 2 diabetes drug, metformin.
Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Eikawa S, et al. Among authors: udono h. Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1809-14. doi: 10.1073/pnas.1417636112. Epub 2015 Jan 26. Proc Natl Acad Sci U S A. 2015. PMID: 25624476 Free PMC article.
Study about the Efficacy of Metformin to Immune Function in Cancer Patients.
Watanabe M, Yamamoto H, Eikawa S, Shien K, Shien T, Soh J, Hotta K, Wada J, Hinotsu S, Fujiwara T, Kiura K, Doihara H, Miyoshi S, Udono H, Toyooka S. Watanabe M, et al. Among authors: udono h. Acta Med Okayama. 2016 Aug;70(4):327-30. doi: 10.18926/AMO/54514. Acta Med Okayama. 2016. PMID: 27549683 Free article.
Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes.
Nishida M, Yamashita N, Ogawa T, Koseki K, Warabi E, Ohue T, Komatsu M, Matsushita H, Kakimi K, Kawakami E, Shiroguchi K, Udono H. Nishida M, et al. Among authors: udono h. J Immunother Cancer. 2021 Sep;9(9):e002954. doi: 10.1136/jitc-2021-002954. J Immunother Cancer. 2021. PMID: 34531248 Free PMC article.
99 results